Related Experiment Video

Updated: Aug 9, 2026

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function
11:47

Treating SCA1 Mice with Water-Soluble Compounds to Non-Specifically Boost Mitochondrial Function

Published on: January 22, 2017

L-carnitine supplementation in childhood epilepsy: current perspectives

D C De Vivo1, T P Bohan, D L Coulter

  • 1Neurological Institute, Columbia-Presbyterian Medical Center, New York, New York 10032, USA.

Epilepsia
|November 20, 1998
PubMed

Insights

L-carnitine supplementation is recommended for children with epilepsy, particularly those on valproate or ketogenic diets. It is crucial for treating valproate-induced liver damage and carnitine deficiency syndromes.

Area of Science:

  • Neurology
  • Metabolic Disorders
  • Pediatric Medicine

Background:

  • A 1996 panel updated 1989 guidelines on L-carnitine supplementation for childhood epilepsy.
  • The panel comprised pediatric neurologists, neurologists, and metabolic experts.

Purpose of the Study:

  • To provide updated consensus recommendations for L-carnitine supplementation in pediatric epilepsy.
  • To address specific indications and dosages for L-carnitine in various pediatric epilepsy scenarios.

Main Methods:

  • A consensus meeting of pediatric neurologists was convened in November 1996.
  • The panel reviewed and updated existing guidelines based on expert consensus.

Main Results:

  • Intravenous L-carnitine is indicated for valproate (VPA)-induced hepatotoxicity, overdose, and acute metabolic crises.
  • Oral L-carnitine is indicated for primary carnitine transporter defects and strongly suggested for secondary deficiencies, VPA-related issues, ketogenic diets, dialysis, and premature infants on TPN.
  • Recommended oral dosage: 100 mg/kg/day (max 2 g/day); IV doses for emergencies may exceed this.

Conclusions:

  • L-carnitine supplementation plays a vital role in managing specific conditions in pediatric epilepsy.
  • Updated guidelines provide clear indications for both intravenous and oral L-carnitine, along with dosage recommendations.

More Related Videos

Lipidomics and Transcriptomics in Neurological Diseases09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons08:04

Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons

Published on: June 6, 2025

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...